ADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1.98%, EPS grew 21.4%, free cash flow grew 19.7% and total debt rose 140.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ADMA
ADMA Biologics Inc (ADMA) P/E ratio
As of 16 October 2026, ADMA Biologics Inc (ADMA) trades at a P/E ratio of 14.8×. Over the past ten years it has ranged from 0.0× (June 2024) to 134× (September 2024); the current reading is higher than 85% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 29.9× | 46.46% |
| FY2024 | 20.4× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 11.6× | (10.97%) |
| Mar 2026 | 13.1× | (56.33%) |
| Dec 2025 | 29.9× | 77.45% |
| Sep 2025 | 16.9× | (19.49%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NAMS NewAmsterdam Pharma Company N.V. compare | n/m |
| SLS SELLAS Life Sciences Group, Inc. compare | n/m |
| MBX MBX Biosciences, Inc. compare | n/m |
| BEAM Beam Therapeutics Inc. compare | n/m |
| CLDX Celldex Therapeutics, Inc. compare | n/m |
| PGEN Precigen, Inc. compare | n/m |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.9× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 12.2× |
| ADMA ADMA Biologics Inc | 14.8× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)